• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JVI: Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly-protective stalk-specific antibodies

tetano

Editor, Senior Moderator
April 2013, doi: 10.1128/​JVI.00641-13



Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly-protective stalk-specific antibodies

Florian Krammer1,
Natalie Pica1,3,
Rong Hai1,
Irina Margine1,3 and
Peter Palese1,2*

+ Author Affiliations

1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
3Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA

ABSTRACT

Current influenza virus vaccine strategies stimulate immune responses towards the globular head domain of the hemagglutinin protein in order to inhibit key steps of the virus lifecycle. Because this domain is highly variable across strains, new vaccine formulations are required in most years. Here we demonstrate a novel vaccine strategy that generates immunity to the highly conserved stalk domain, using chimeric hemagglutinin constructs that express unique head and stalk combinations. By repeatedly immunizing with constructs that express the same stalk but an irrelevant head, we specifically stimulate a stalk-directed response that provides broad-based heterologous and heterosubtypic immunity in mice. Notably, our vaccination scheme provides a universal vaccine approach that protects against challenge with an H5 subtyped virus. Furthermore, through in vivo studies using passively transferred antibodies or depletion of CD8+ T cells, we demonstrate the critical role that humoral mechanisms of immunity play in the protection observed. The present data suggest that a vaccine strategy based on the stalk domain of the hemagglutinin protein could be used in humans to broadly protect against a variety of influenza virus subtypes.


http://jvi.asm.org/content/early/2013/04/04/JVI.00641-13.abstract
 
Back
Top Bottom